ArticleJCEM case reports2025
Type 2 Diabetes in a 4-Year-Old With Obesity: Considerations for Use of Semaglutide and Bariatric Surgery in Children.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of youth-onset type 2 diabetes (T2D) in children necessitates early intervention with tight glycemic control, obesity medications, and metabolic and bariatric surgery (MBS). Insulin and metformin are standard treatments, but additional therapies for obesity in youth are needed. A 4-year-old Hispanic female with early-onset obesity and newly diagnosed T2D presented with a hemoglobin A1c (HbA1c) level of 8.0% (reference: < 5.7%), a fasting glucose of 147 mg/dL (SI units: 8.17 mmol/L) (reference: 70-115 mg/dL [3.33-6.39 mmol/L]), and a body mass index (BMI) of 41 kg/m². She had rapid weight gain and hyperphagia. Initially, insulin therapy was started, and her HbA1c decreased to 6.7% over 6 months. Insulin was discontinued and metformin 1000 mg twice daily was started. Topiramate 75 mg nightly was prescribed for obesity with minimal effect and so semaglutide was started and titrated to 2 mg weekly. By 27 months, her HbA1c improved to 5.1%, and overall, she had a 12% reduction in her percent above the 95th percentile (%BMI
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.